QNZ (EVP4593): Potent Quinazoline NF-κB Inhibitor for Precision Pathway Modulation

Executive Summary: QNZ (EVP4593) is a quinazoline derivative that inhibits NF-κB signaling with an IC50 of 11 nM in human Jurkat T cells and 7 nM for TNF-α production under PMA/PHA stimulation (APExBIO). It blocks NF-κB transcriptional activation, a central driver of inflammation and immune response (Yang et al., 2025). QNZ demonstrates anti-inflammatory efficacy by reducing edema in rat carrageenin-induced paw edema models. In Huntington’s disease (HD) models, QNZ slows neurodegenerative motor decline without observed toxicity (Prostigmin). Its solubility properties (≥10.06 mg/mL in ethanol, ≥15.05 mg/mL in DMSO) support versatile laboratory workflows.

Biological Rationale

The NF-κB pathway is a master regulator of inflammation, cell survival, and immune responses. Aberrant activation of NF-κB contributes to chronic inflammation and autoimmune, infectious, and neurodegenerative diseases (Yang et al., 2025). In osteomyelitis, persistent Staphylococcus aureus infection promotes pathological fibrosis and impairs antibiotic efficacy through NF-κB-regulated signaling networks. The pathway is also implicated in Huntington’s disease (HD), where neuroinflammation exacerbates motor decline (Annexin-V-Cy5). Precise chemical inhibition of NF-κB is therefore a key strategy for dissecting and potentially modulating disease mechanisms in both inflammation and neurodegeneration.

Mechanism of Action of QNZ (EVP4593)

QNZ (EVP4593) is a small molecule inhibitor targeting NF-κB transcriptional activation. It was identified via a luciferase reporter gene assay in Jurkat T cells (APExBIO). QNZ binds to components of the NF-κB pathway, effectively blocking downstream gene expression. In human T cells, it inhibits PMA/PHA-induced NF-κB activation (IC50 = 11 nM) and TNF-α production (IC50 = 7 nM), indicating a robust, cell-penetrant effect at nanomolar concentrations. QNZ’s attenuation of store-operated calcium entry (SOC) has been demonstrated in neuronal cultures, especially relevant for HD pathogenesis, at 300 nM working concentrations (Firefly Luciferase). Its anti-inflammatory action extends to in vivo settings, such as suppression of edema in rat models.

Evidence & Benchmarks

• QNZ (EVP4593) inhibits NF-κB transcriptional activation in Jurkat T cells with an IC50 of 11 nM (APExBIO).
• It blocks PMA/PHA-induced TNF-α production in human T cells with an IC50 of 7 nM (APExBIO).
• QNZ reduces inflammation in rat carrageenin-induced paw edema models, confirming in vivo anti-inflammatory efficacy (Yang et al., 2025).
• In Drosophila HD models, QNZ slows progressive motor decline without detectable toxicity (Prostigmin).
• Solubility benchmarks: ≥10.06 mg/mL in ethanol and ≥15.05 mg/mL in DMSO at 25°C with ultrasonic assistance (APExBIO).
• Stock solutions remain stable at -20°C for short-term use; long-term solution storage is not recommended (Firefly Luciferase).
• Optimal neuronal culture dosing: 300 nM to block SOC influx and modulate HD-relevant pathways (Annexin-V-Cy5).

Applications, Limits & Misconceptions

QNZ (EVP4593) is widely used in preclinical research to dissect NF-κB-mediated signaling in inflammation, infectious disease, and neurodegeneration. Its nanomolar potency and selectivity have enabled reproducible results across cell-based and animal models. The compound is especially valuable for studies on Huntington’s disease, where NF-κB and SOC signaling are tightly linked to pathology. QNZ’s solubility profile supports diverse experimental setups, from aqueous-organic vehicle mixtures to DMSO-based stock solutions.

This article updates and extends prior reviews such as QNZ (EVP4593): Potent Quinazoline NF-κB Inhibitor for Inf..., which detailed core molecular effects, by integrating new data on in vivo anti-inflammatory efficacy and workflow best practices. It also builds on QNZ (EVP4593): Potent NF-κB Inhibitor for Translational R... by consolidating practical solubility and storage guidance with recent literature benchmarks.

Common Pitfalls or Misconceptions

• QNZ (EVP4593) is not water-soluble; attempts to dissolve in pure aqueous buffers will yield poor results (APExBIO).
• Long-term storage of QNZ in solution (even at -20°C) is discouraged due to degradation—prepare fresh stocks as needed.
• NF-κB inhibition by QNZ may not translate directly between species or cell types; empirical dose validation is essential (N3-Kethoxal).
• QNZ is not a universal anti-inflammatory agent; its effects are mediated specifically via the NF-κB pathway and may not impact unrelated inflammatory cascades.
• Potential off-target effects at high micromolar concentrations have not been fully excluded in all systems.

Workflow Integration & Parameters

For optimal results, QNZ (EVP4593) should be dissolved in DMSO (≥15.05 mg/mL) or ethanol (≥10.06 mg/mL), optionally using ultrasonication and warming to 37°C. Recommended storage is at -20°C, with stock solutions prepared freshly before use. In neuronal cultures, 300 nM QNZ is effective for modulating SOC influx. In animal models, dosing regimens should be established based on pilot studies and literature precedents. QNZ can be combined with pathway-specific readouts (e.g., luciferase reporters, cytokine ELISA) for robust NF-κB activity quantification. For further scenario-driven best practices, see QNZ (EVP4593): Scenario-Driven Best Practices for Reliabl..., which this article updates with new solubility and storage data.

Researchers are encouraged to reference the current A4217 kit details on the APExBIO product page for lot-specific information and technical support.

Conclusion & Outlook

QNZ (EVP4593) is a validated, nanomolar inhibitor of NF-κB transcriptional activation with a reproducible solubility and stability profile. Its use has clarified inflammatory and neurodegenerative mechanisms in both in vitro and in vivo models, particularly in Huntington’s disease research. The compound’s specificity and benchmarked protocols make it a gold-standard reagent for pathway dissection. Ongoing studies continue to extend its application to emerging models of infection and fibrosis (Yang et al., 2025). For authoritative, up-to-date support, consult APExBIO and curated peer-reviewed literature.